Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr51.25 SEK
Change Today -0.75 / -1.44%
Volume 35.8K
NVP On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 11:30 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

neurovive pharmaceutical (NVP) Snapshot

Open
kr52.50
Previous Close
kr52.00
Day High
kr52.50
Day Low
kr50.25
52 Week High
08/5/14 - kr82.00
52 Week Low
05/7/14 - kr22.00
Market Cap
1.5B
Average Volume 10 Days
70.4K
EPS TTM
kr-1.79
Shares Outstanding
29.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROVIVE PHARMACEUTICAL (NVP)

Related News

No related news articles were found.

neurovive pharmaceutical (NVP) Related Businessweek News

No Related Businessweek News Found

neurovive pharmaceutical (NVP) Details

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. Its product portfolio includes CicloMulsion, a drug candidate, which is in Phase III clinical study for cell protection against reperfusion injury during heart attack treatment; NeuroSTAT, a drug candidate that is in Phase IIa clinical study for the treatment of traumatic brain injuries; and NVP019, an intravenous formulation that is in pre-clinical phase for treating myocardial infarct and traumatic brain injury. The company is also developing NVP014 for brain cell protection in stroke; NVP015 for treating mitochondrial diseases in children and drug-induced mitochondrial dysfunction; and NVP018, an antiviral pharmaceutical product to treat hepatitis B and C. It has collaboration agreements with Isomerase Therapeutics and Sihuan Pharmaceutical; and development and commercialization outlicensing agreement with OnCore BioPharma, as well as agreements with Fresenius Kabi and Lyon University Hospital. The company was founded in 2000 and is headquartered in Lund, Sweden.

Founded in 2000

neurovive pharmaceutical (NVP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr2.0M
Compensation as of Fiscal Year 2014.

neurovive pharmaceutical (NVP) Key Developments

Neurovive Pharmaceutical AB Announces Clinical Phase II Study for Kidney Protection During Heart Surgery

NeuroVive Pharmaceutical AB announced that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company’s product CicloMulsion. The study, known as CiPRICS, is being conducted by Skåne University Hospital and will evaluate the product’s ability to prevent acute kidney injury during heart surgery. The CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) study is a double-blind, randomized and placebo-controlled clinical phase II study. The study will include a total of 150 patients at the department of Cardiothoracic Surgery at Skåne University Hospital in Lund, which also initiated the study. Patients will be treated with CicloMulsion® or placebo prior to coronary bypass surgery. The aim is to evaluate whether pre-treatment with a mitochondria-protecting drug protects the kidneys against injury and prevents the compromised renal function that can result from altered blood supply during cardiac surgery. In addition to the patients’ renal function, which will be closely monitored, other markers, such as markers for cardiac injury, will be analyzed.

NeuroVive Pharmaceutical AB Announces Clinical Phase II Study with NeuroSTAT for Traumatic Brain Injury Passes Safety Evaluation

NeuroVive Pharmaceutical AB announced that the independent safety committee has endorsed moving on to the next dose level without any safety issues, following the treatment of 10 of 20 patients in the ongoing clinical Phase IIa study for traumatic brain injury with the company's drug candidate NeuroSTAT. Consequently, the study will continue as planned and move on to the next dosage group. The ongoing CHIC study (Copenhagen Head Injury Ciclosporin Study) is an open-label, non-comparative clinical Phase IIa study enrolling a total of 20 patients divided into two different dosage groups, where NeuroVive's drug candidate NeuroSTAT is being evaluated for the treatment of patients with traumatic brain injury. The study is being conducted at the Department of Neurosurgery at Rigshospitalet, University of Copenhagen, with MD. Jesper Kelsen as Principal Investigator. The study's first dosage group of 10 patients has now been treated with NeuroSTAT at the lower dose, and an interim analysis has been completed by an independent safety committee in order to evaluate the treatment's safety profile. The analysis includes an evaluation of blood concentrations of cyclosporin A (the active substance in NeuroSTAT) and changes in intracranial pressure and blood samples collected to analyze possible organ injury. The low-dose treatment is judged to be safe and the study will now continue as planned with the higher dosage group including 10 additional patients.

NeuroVive Pharmaceutical AB Establishes Subsidiary in Lyon

NeuroVive Pharmaceutical AB has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with Hospices Civils de Lyon (HCL) and Professor Michel Ovize (the OPeRa program) to include drug development for the treatment of stroke. The creation of a legal entity in France also coincides with preparations for the potential commercialization of the company’s product CicloMulsion®. The establishment of a French subsidiary, NeuroVive France, increases NeuroVive’s presence in the country while simultaneously extending the partnership with HCL to include drug development for the treatment of stroke. The establishment of a French subsidiary enables NeuroVive to participate as an industrial partner in applications for national funding in France (RHU grants). An application for close to EUR 10 m in funding during a five-year period which includes NeuroVive alongside HCL and other industrial partners has already been submitted.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVP:SS kr51.25 SEK -0.75

NVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVP.
View Industry Companies
 

Industry Analysis

NVP

Industry Average

Valuation NVP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 162.4x
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 164.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROVIVE PHARMACEUTICAL, please visit www.neurovive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.